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metabolite of clopidogrel and its antiplatelet effects. Meanwhile, ABCB1 C3435T also
plays an important role in intestinal absorption of clopidogrel, which will further affect
the exposure to clopi-H4.
GW25-e0513
Impact of obesity on long-term outcomes in patients with acute coronary
syndrome and without diabetes
Sheng-Yong Dong1,2, Man-Liu Wang3, Hang Xiang1, Qiang Zeng1
1International Medical Center, Chinese PLA General Hospital, Beijing 100853,
China, 2Healthcare Department of Management and Logistic Support Department,
General Staff Department of PLA, Beijing 100034, China, 3Center of Biomedical
Analysis, Tsinghua University, Beijing 100084, China
Objectives: Obesity is associated with an increased cardiovascular events in the
general population. However, recent studies have shown a paradoxic relation between
obesity and adverse outcomes in patients with type 2 diabetes, coronary artery disease,
heart failure, or hypertension. However, whether this phenomenon exists in patients
with acute coronary syndrome (ACS) but without diabetes is not known. The aim of
the study was to assess the impact of obesity on adverse outcomes in patients with
acute coronary syndrome (ACS) but without diabetes.
Methods: A total of 571 patients with ACS but without diabetes (72.5% was men,
mean age was 59.9  11.2 years) were included in a retrospective study, and with at
least 3 years’ follow-up. The endpoint events were major adverse cardiovascular
events (MACE), which included cardiac death, non-fatal myocardial infarction, and
rehospitalization with unstable angina. The primary outcomes were cardiac death and
non-fatal myocardial infarction. Patients were classiﬁed into 3 groups according to
baseline body mass index (BMI): less than 24 kg/m2 (normal weight), 24 to 28 kg/m2
(overweight), and 28 kg/m2 or more (obese).
Results: The incidence of long-term MACE was 33.6% and decreased with the levels
of BMI (the incidences of MACE were 37.9%, 34.1%, and 25.2%, respectively,
P trend¼0.031). Obese patients had a lower risk of MACE than their normal weight
counterparts (hazard ratio (HR) ¼0.58; 95% conﬁdence interval (CI), 0.37-0.91;
P¼0.016). After multivariable adjustment, the lower risk of MACE in obese patients
remained signiﬁcant (HR¼0.60; 95% CI, 0.39-0.94; P¼0.027). The overweight pa-
tients also had a lower risk of MACE than the normal weight patients in the single and
the multiple variables Cox models, but the differences were not signiﬁcant (the
P values were 0.271 and 0.272 in the single and multiple variables models, respec-
tively). Furthermore, the risks of the primary outcomes also decreased with BMI levels
in the single and multiple variables models, but all of the differences were not sta-
tistically signiﬁcant (P>0.05 for all).
Conclusions: In a population with ACS but without diabetes, obese patients had a
decreased risk of major adverse cardiovascular events compared with their normal
weight counterparts. In concordance with data in patients with diabetes, coronary
artery disease, hypertension, or heart failure, our ﬁndings further suggest a protective
effect of obesity on long-term outcomes in patients with ACS but without diabetes.
Furthermore, multi-center and large-scale prospective study are needed to evaluate the
ﬁndings.
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Objectives: To measure the concentration of GDF-15 in patients with STEMI and to
evaluate its potential to predict heart failure in this group of patients.
Methods: Fifty nine STEMI patients who were admitted to the hospital within 6 hours
of symptom onset were enrolled in the study. Biomarkers were measured both
immediately at the time of STEMI diagnosis and 24 hours later. Killip classiﬁcation
was evaluated 24 hours after admission.
Results: GDF-15 levels were high at the time of admission and were positively
correlated with both Killip classiﬁcation and pulmonary artery systolic pressure
(PASP). Brain natriuretic peptide (BNP) signiﬁcantly increased 24 hours after
admission and also positively correlated with Killip classiﬁcation and PASP. How-
ever, at the time of admission, there was no signiﬁcant correlation. One-way ANOVA
revealed signiﬁcant differences in GDF-15 concentrations among the different Killip
classes. Based on the receiver-operating-characteristic (ROC) curve, we determined
that a value of 716.6 pg/mL corresponded to a Killip classiﬁcation greater than Class
II; a value of 1021.1 pg/mL corresponded to a classiﬁcation higher than Class III.
Other biomarkers that were assessed in the study included TnT, IL-6, IL-8, IL-10, and
MCP-1; none of these markers correlated with either PASP or Killip class.
Conclusions: In patients with STEMI, GDF-15 is increased prior to BNP. GDF-15
may predict risk of congestive heart failure following STEMI.
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coronary artery disease (CAD) remains unclear. The present study aimed to determine
the association between OSA severity and Gensini score detected by 320-slice cor-
onary CTA in suspected CAD patients.
Methods: A total of 285 consecutive men (age: 60.3 9.8 years; BMI: 27.5  5.8 kg/
m2) who received polysomnography and 320-slice coronary CTA for suspected CAD
were included. Patients with prior revascularization were excluded. Suspected CAD
depended on angina-like symptoms, elevated cardiovascular risk, abnormal echocar-
diogram, positive stress ECG test and/or myocardial perfusion scintigraphies. OSA
was diagnosed according to polysomnography when the apnea-hypopnea index (AHI)
is greater than 5. Gensini scores, a method to evaluate the severity of coronary artery
disease, were gathered from 320-slice coronary CTA using the AHA 15-segment
model of coronary trees. The volunteers were divided to three groups according to
AHI: no-OSA group (AHI5), mild-OSA group (5<AHI<30) and severe-OSA group
(AHI30). Gensini scores were compared among groups using two-way ANOVA.
Spearman coefﬁcient was calculated to explore the correlation between AHI and
Gensini scores. p<0.01 was considered statistically signiﬁcant.
Results: Based on AHI, 153 patients were categorized into no-OSA group, 84 into
mild-OSA group and 48 into severe-OSA group. There were no statistical differences
among three groups in BMI, blood pressure, serum lipid level and blood glucose level.
Compared with no-OSA group, Gensini scores in mild-OSA (34.7217.47 vs
20.9613.27, p<0.01) and severe-OSA group (55.3420.57 vs 20.9613.27
p<0.01) were signiﬁcantly higher. Moreover, Gensini score in mild-OSA group was
signiﬁcantly lower than severe-OSA group (34.7217.47 vs 55.3420.57, p<0.01).
Spearman coefﬁcient indicated that the AHI of OAS positively correlated with Gensini
scores (r¼0.578, p<0.01).
Conclusions: Our study found an obvious correlation between OSA severity and
Gensini score in suspected CAD patients. OSA severity should be an assessment of
CAD risk.
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Objectives: Clinical trials produced conﬂicting results of routine intracoronary
thrombus aspiration (TA) before primary percutaneous coronary intervention (PCI) in
ST-segment elevation myocardial infarction (STEMI) patients. This study was to
perform an updated meta-analysis of randomized trials to evaluate all-cause death
events, other clinical outcomes [major adverse cardiac event (MACE), re-myocardial
infarction (Re-MI), stent thrombosis (ST), target-vessel revascularization (TVR),
target-lesion revascularization (TLR) ] and the makers of myocardial reperfusion
between TA prior to PCI (TA+PCI) compared with PCI only in STEMI patients.
Methods: The primary sources were the electronic databases of PubMed, Embase,
and the Cochrane Library from January 1990 to November 2013. Randomized clinical
trials comparing sildenaﬁl to placebo, in heart failure patients, reporting at least one
outcome of interest were included. Data were extracted regarding the characteristics
and clinical outcomes, and combined using a ﬁxed or random effect meta-analysis.
Results: A total of 25 randomized trials with 12940 patients were included. TA+PCI
A total of 25 randomized trials with 12940 patients were included. TA+PCI was
associated with signiﬁcant beneﬁts in terms of all-cause death in 6 months follow-up
(P ¼ 0.03) but not in 30 days (P ¼ 0.20). As for other clinical outcomes in 30 days
follow-up, TA+PCI was only associated with a trend of lower Re-MI rate, and in 6
months follow-up, TA+PCI had signiﬁcant lower rates of MACE, Re-MI and TLR as
compared with PCI only. Besides, TA+PCI were associated with signiﬁcantly
improved markers of myocardial reperfusion.
Conclusions: TA+PCI was associated with signiﬁcant beneﬁts in terms of all-cause
death, MACE, Re-MI and TLR in 6 months follow-up but not in 30 days follow-up,
with signiﬁcantly improved markers of myocardial reperfusion. Thus, TA is recom-
mended for routine use among STEMI patients undergoing PCI for long term
consideration.
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Objectives: The study was to access the association between resting heart rate (RHR)
and 1-year risk of major adverse cardiovascular events (MACE) in acute coronary
syndrome (ACS) patients after percutaneous coronary intervention (PCI).
Methods: A total of 808 participants with ACS after successful PCI were assigned to
the conventional treatment. MACE was deﬁned as a composite of cardiac death,
nonfatal recurrent myocardial infarction (MI), ischemic-driven revascularization, and9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
